Thanks for your input mate. Regarding your first point, it was not clear to me whether Merck's drug was administered together with the statin (like NYR would seek to do), or administered as a single agent to patients who had already tried statin as a first line therapy. I wonder if this makes a difference at all?
I also don't think it is apples to apples, as Merck's results were in human subjects in phase 1 trials. Does anybody know how accurate the mouse models NYR used tend to be in terms of predicting similar results in humans?
Cheers
NYR Price at posting:
21.0¢ Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)